Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG

SG&A Trends: TG Therapeutics vs. MorphoSys Over a Decade

__timestampMorphoSys AGTG Therapeutics, Inc.
Wednesday, January 1, 2014968900024518692
Thursday, January 1, 20151043100019886580
Friday, January 1, 2016961800012631689
Sunday, January 1, 20171234800021977998
Monday, January 1, 20182831024120759000
Tuesday, January 1, 20195933614720838000
Wednesday, January 1, 2020159145941121812000
Friday, January 1, 2021199800000152137000
Saturday, January 1, 20229022500083231000
Sunday, January 1, 202392538000122706000
Loading chart...

In pursuit of knowledge

A Decade of SG&A: TG Therapeutics vs. MorphoSys

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, TG Therapeutics, Inc. and MorphoSys AG have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, MorphoSys AG's SG&A expenses surged by over 850%, peaking in 2021. Meanwhile, TG Therapeutics, Inc. saw a more modest increase of approximately 500% during the same period, with a notable spike in 2020. This divergence highlights differing strategic priorities and market responses. While MorphoSys AG's expenses reflect aggressive expansion, TG Therapeutics' steadier growth suggests a more conservative approach. As both companies navigate the complexities of the biotech sector, their SG&A trajectories offer valuable insights into their operational strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025